Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Perrigo Company plc's recent earnings for Q2 2024 revealed both strengths and challenges within its portfolio of products and strategic initiatives.</li><li>Under the leadership of CEO Patrick Lockwood-Taylor, the company has made significant progress in restructuring its operations and cost management, which is reflected in select financial strengths and strategic positioning evident in the quarterly outcomes.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Perrigo Company plc's recent earnings for Q2 2024 revealed both strengths and challenges within its portfolio of products and strategic initiatives.Under the leadership of CEO Patrick Lockwood-Taylor, the company has made significant progress in restructuring its operations and cost management, which is reflected in select financial strengths and strategic positioning evident in the quarterly outcomes.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Perrigo Company plc: Its Competitive Positioning Driving Our Bullish Rating? - Major Drivers

External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

<ul><li>PRGO has resolved 90% of its challenges and is on track to address the remaining issues soon</li><li>Predicted rise in earning power by 2025 could boost estimates and valuation, with potential for $3.5 EPS and $45 price target</li><li>New CEO has shown progress in addressing issues, setting new expectations, and implementing cost-cutting measures, making PRGO an attractive investment opportunity with limited downside risk</li></ul>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

PRGO has resolved 90% of its challenges and is on track to address the remaining issues soonPredicted rise in earning power by 2025 could boost estimates and valuation, with potential for $3.5 EPS and $45 price targetNew CEO has shown progress in addressing issues, setting new expectations, and implementing cost-cutting measures, making PRGO an attractive investment opportunity with limited downside riskThis content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Perrigo Co Plc (PRGO) - Thursday, Jul 4, 2024

<ul><li>Perrigo's first quarter 2024 financial results reflect a business in recovery and transition, marked by strategic initiatives aimed at long-term growth despite immediate challenges.</li><li>The company reported a net sales decrease of 8%, primarily driven by its infant formula business and SKU prioritization actions.</li><li>Organic net sales declined by 7%, with infant formula alone accounting for a 4.3 percentage point drop.</li></ul>

Perrigo's first quarter 2024 financial results reflect a business in recovery and transition, marked by strategic initiatives aimed at long-term growth despite immediate challenges.The company reported a net sales decrease of 8%, primarily driven by its infant formula business and SKU prioritization actions.Organic net sales declined by 7%, with infant formula alone accounting for a 4.3 percentage point drop.

Perrigo Company plc: A Dive Into Its Business Strategy & 5 Factors For Our 'Buy' Rating! - Financial Forecasts

Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

It's time for the S&amp;P500 Index Rebalance. Friday night on 3 Sep ahead of the long weekend we got the <a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20210903-1443045/1443045_sept2021-546-shuf-rebal.pdf" target="_blank" rel="noopener">announcement</a> from S&amp;P Dow Jones Indices. This quarter we have 3 Additions...<ul>
<li>
<a href="https://www.smartkarma.com/entities/match-group-inc" target="_blank" data-smartkarma-citation="entities:25903:1" rel="noopener">Match Group Inc (MTCH US)</a> </li>
<li>
<a href="https://www.smartkarma.com/entities/ceridian-hcm-holding-inc" target="_blank" data-smartkarma-citation="entities:27122:1" rel="noopener">Ceridian HCM Holding Inc (CDAY US)</a> </li>
<li>
<a href="https://www.smartkarma.com/entities/brown-brown-inc" target="_blank" data-smartkarma-citation="entities:19532:1" rel="noopener">Brown &amp; Brown (BRO US)</a> </li>
</ul>Combined, the three ADDITIONS had US$6.4bn of revenue in the last 12 months, US$1.6bn of OP in that time, and they are forecast to have OP of $1.97bn in the next 12 months.and 3 Deletions... <ul>
<li>
<a href="https://www.smartkarma.com/entities/perrigo-co-plc" target="_blank" data-smartkarma-citation="entities:869:1" rel="noopener">Perrigo Co Plc (PRGO US)</a> </li>
<li>
<a href="https://www.smartkarma.com/entities/unum-group" target="_blank" data-smartkarma-citation="entities:2521:1" rel="noopener">Unum Group (UNM US)</a> </li>
<li><a href="https://www.smartkarma.com/entities/national-oilwell-varco-inc" target="_blank" data-smartkarma-citation="entities:3046:1" rel="noopener">National Oilwell Varco (NOV US)</a></li>
</ul>Combined, the three DELETIONS had US$21.97bn of revenue in the last 12 months, US$1.1bn of OP in that time, and they are forecast to have $2.13bn of OP in the next 12 months.<div class="content-highlight">
With 3+x the revenue and a combined OP forecast 8% higher than the ADDITIONS in the next 12 months, these three DELETIONS have a combined market cap of US$16bn as of Friday's close against the combined market cap of the ADDITIONS which are at US$75bn.
That may not make much sense but most major indices are like that - they buy what goes up, after it has gone up, and they sell what underperforms, after it has underperformed. 
</div>While these names are not really a surprise, they may prove interesting.Much more analysis below the fold.

It's time for the S&amp;P500 Index Rebalance. Friday night on 3 Sep ahead of the long weekend we got the announcement from S&amp;P Dow Jones Indices. This quarter we have 3 Additions...

Match Group Inc (MTCH US) 

Ceridian HCM Holding Inc (CDAY US) 

Brown &amp; Brown (BRO US) 
Combined, the three ADDITIONS had US$6.4bn of revenue in the last 12 months, US$1.6bn of OP in that time, and they are forecast to have OP of $1.97bn in the next 12 months.and 3 Deletions... 

Perrigo Co Plc (PRGO US) 

Unum Group (UNM US) 
National Oilwell Varco (NOV US)
Combined, the three DELETIONS had US$21.97bn of revenue in the last 12 months, US$1.1bn of OP in that time, and they are forecast to have $2.13bn of OP in the next 12 months.
With 3+x the revenue and a combined OP forecast 8% higher than the ADDITIONS in the next 12 months, these three DELETIONS have a combined market cap of US$16bn as of Friday's close against the combined market cap of the ADDITIONS which are at US$75bn.
That may not make much sense but most major indices are like that - they buy what goes up, after it has gone up, and they sell what underperforms, after it has underperformed. 
While these names are not really a surprise, they may prove interesting.Much more analysis below the fold. 

S&P500 September 2021 Rebalance:  3 OUT, 3 IN - The Deletions May Be More Interesting

<ul><li>Perrigo Company plc's fourth quarter and 2023 fiscal year results displayed stable growth in the company's core operations, with an organic net sales increase of 2% for the year and EPS growth of 25% to $2.58, exceeding the prior year.</li><li>Dimension such as significant growth in Skin Care, nutrition, and women's health categories, as well as solid progress in the healthy lifestyle sector, underscore the company's positive performance.</li><li>Also contributing were supply chain reinvention program savings of $40 million and the strategic acquisition of HRA offering synergies of $30 million.</li></ul>

Perrigo Company plc's fourth quarter and 2023 fiscal year results displayed stable growth in the company's core operations, with an organic net sales increase of 2% for the year and EPS growth of 25% to $2.58, exceeding the prior year.Dimension such as significant growth in Skin Care, nutrition, and women's health categories, as well as solid progress in the healthy lifestyle sector, underscore the company's positive performance.Also contributing were supply chain reinvention program savings of $40 million and the strategic acquisition of HRA offering synergies of $30 million.

Perrigo Company plc's fourth quarter and 2023 fiscal year results displayed stable growth in the company's core operations

United States

Perrigo Company PLC is a global healthcare supplier that develops, manufactures, and distributes OTC and generic prescription pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients and pharmaceutical and medical diagnostic products. The Company's primary markets and locations of manufacturing and logistics operations are the US, UK, Mexico, and Australia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Perrigo (PRGO US)

Perrigo Company plc: Its Competitive Positioning Driving Our Bullish Rating? - Major Drivers

Perrigo Company plc's recent earnings for Q2 2024 revealed both strengths and challenges within its portfolio of products and strategic...

Baptista Research

Perrigo Co Plc (PRGO) - Thursday, Jul 4, 2024

PRGO has resolved 90% of its challenges and is on track to address the remaining issues soon. Predicted rise in earning power by 2025 could boost...

Value Investors Club

Perrigo Company plc: A Dive Into Its Business Strategy & 5 Factors For Our 'Buy' Rating! - Financial Forecasts

Perrigo's first quarter 2024 financial results reflect a business in recovery and transition, marked by strategic initiatives aimed at long-term...

Baptista Research

S&P500 September 2021 Rebalance: 3 OUT, 3 IN - The Deletions May Be More Interesting

The S&P500 Quarterly Review is here. 3 in and 3 out. $14bn a side as of now. I expect the DELETIONS are more interesting though the headlines will...

Travis Lundy

Perrigo Company plc's fourth quarter and 2023 fiscal year results displayed stable growth in the company's core operations

Perrigo Company plc's fourth quarter and 2023 fiscal year results displayed stable growth in the company's core operations, with an organic net...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)